Drug intelligence / Profile preview

SIR-X3

Development stage: Preclinical
Lead developer: Sironax

Overview

SIR-X3 is a discovery-stage drug candidate being developed by Sironax. As of the latest pipeline information, the specific biological target, mechanism of action, and intended therapeutic indications for SIR-X3 have not been disclosed. Sironax is a biotechnology company focused on developing therapies for neurodegenerative and inflammatory diseases, particularly those involving programmed cell death pathways such as necroptosis and axon degeneration.

Beyond the preview

Go deeper on SIR-X3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-X3.

Explore the full profile